Cubist acquires rights to ceftolozane from Astellas

Cubist Pharmaceuticals has acquired the remaining rights to ceftolozane for the treatment of  urinary tract infections, in certain Asia-Pacific and Middle East territories from Astellas Pharma Inc. Cubist will now own worldwide rights to develop, manufacture and commercialize the drug, which in combination with tazobactam is currently being studied in two third-round trials as a potential first-line intravenous therapy for treating complicated intra-abdominal infections and urinary tract infections.